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Abstract
Background: Patients with systemic sclerosis (SSc) are endagered by tissue fibrosis and by microvasculopathy, with
the latter caused by endothelial cell expansion/proliferation. SSc-associated fibrosis potentially results from
mesenchymal transdifferentiation of endothelial cells. Early Endothelial Progenitor Cells (eEPCs) act proangiogenic
under diverse conditions. Aim of the study was to analyze eEPC regeneration and mesenchymal transdifferentiation
in patients with limited and diffuse SSs (lSSc and dSSc).
Methods: Patients with both, lSSc and dSSc were included into the study. The following parameters were evaluated:
eEPC numbers and regeneration, concentrations of vasomodulatory mediators, mesenchymal properties of
blood-derived eEPC. Serum samples of healthy subjects and SS patients were used for stimulation of cultured human
eEPC, subsequently followed by analysis of mesenchymal cell characteristics and mobility.
Results: Twenty-nine patients were included into the study. Regenerative activity of blood-derived eEPCs did not differ
between Controls and patients. Circulating eEPC were significantly lower in all patients with SSc, and in limited
and diffuse SSc (lSSc/dSSc). Serum concentrations of promesenchymal TGF-b was elevated in all patients with
SSc. Cultured mononuclear cells from SS patients displayed higher abundances of CD31 and of CD31 and aSMA
combined. Finally, serum from SSc patients inhibited migration of cultured eEPCs and the cells showed lower
sensitivity towards the endothelin antagonist Bosentan.
Conclusions: The eEPC system, which represents an essential element of the endogenous vascular repair machinery is
affected in SSc. The increased appearance of mesenchymal properties in eEPC may indicate that alterations of the cells
potentially contribute to the accumulation of connective tissue and to vascular malfunction.
Background
Systemic Sclerosis (SSc) is characterized by severe
microvasculopathy, causing ongoing hypoperfusion of
skin and inner organs [1]. Pathological analysis reveals
endothelial cell proliferation in small blood vessels,
subsequently leading to vascular obstruction (‘onion
skin lesions’) [2]. Another hallmark in SSc is the
accumulation of collagen fibers in skin, lungs, heart, and
intestine. Such fibrosis or sclerosis can dramatically affect
the functional integrity of organs/the whole organism [3].
The etiopathogenesis of the disease is far from being
understood and although therapeutic measures are often
intended to modulate the immune response in order
to inhibit vasculopathy and fibrogenesis, the prognosis
of SSc patients is quite poor since the course of the
disease remains unaffected by drug therapy in many
cases [4]. Thus, it can at least be doubted whether
the cellular and molecular processes, responsible for
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endothelial cell proliferation and collagen accumula-
tion are exclusively autoimmune by nature.
The field of vascular biology has significantly been
emerged in recent years. This is particularly the case
with regard to vascular repair mechanisms. In 1997,
Asahara and colleagues described a population of blood-
derived cells, critically involved in neovascularization [5].
These cells, termed Endothelial Progenitor Cells (EPCs)
are heterogenous in terms of origin and phenotype
[6–8]. They can promote post-ischemic vascular regener-
ation by both, direct and indirect mechanisms. Early
Endothelial Progenitor Cells (eEPC) represent one major
subpopulation of EPCs and they have meanwhile been
used for therapeutic purposes in different experimental
situations and in humans suffering from ischemic diseases
[9–13]. Several recent investigations evaluated numbers of
circulating eEPC in SSc [14–16]. However, in none of the
studies, regenerative activity of eEPC was analyzed in SSc.
We therefore aimed to quantify eEPC regeneration in SSc
and utilized a Colony-Forming Unit Assay as described
and reviewed previously [11, 17–19]. Our particular inter-
est focused on phenotypic characteristics, possibly associ-




The present investigation was a prospective single-
center analysis. All patients were treated at the de-
partment of nephrology and rheumatology (University
Hospital of Göttingen, Germany) between 2011 and
2013. All included individuals were classified according to
the 2013 ACR(American College of Rheumatology)/
EULAR(European League Against Rheumatism) criteria
[20]. Differentiation between limited and diffuse SSc was
made in accordance with the criteria published by LeRoy
and Medsger [21]. The term ‘diffuse (generalized) disease’
is intended to describe patients with skin involvement, ex-
tended even to proximal areas of arms and legs including
possible manifestations at the trunk (thorax and abdo-
men). These patients suffer more often and, if present, in
many cases from more serious organ involvement. How-
ever, patients with limited disease may also show organic
manifestations such as interstitial lung disease and
esophageal damage. Lung involvement was defined as a
lower than normal diffusion capacity (below 80 % of the
nominal value) and/or as interstitial lung affection in
radiographic analysis (chest x-ray or CT (Computed
Tomography) scan) and/or as pulmonary hypertension.
The latter was diagnosed by transthoracic echocardio-
gram. Esophageal manifestation was defined as either per-
sistent dysphagea and/or as pathological esophagram.
Joint affection was defined clinically if patients suffered
from arthralgia. Renal involvement was defined by either
increased serum creatinine and/or by proteinuria of
above 150 mg/day. The patients underwent variable
treatment regimens including administration of im-
munosuppressants for different reasons. For further
clinical characterization a number of different param-
eters, such as c-reactive protein and different auto-
antibodies including anti-Scl70 and anti-Centromer
were measured and collected in the database of the
Clinic of Nephrology & Rheumatology (University
Hospital of Göttingen, Germany). The control sub-
jects (n = 16) matched the patients in terms of gender
and age. They also signed written consent. Individuals
in the control group were recruited from the staff of
the University Hospital of Göttingen.
eEPC quantification and regeneration
Quantification of peripheral circulating eEPC and ana-
lysis of eEPC regeneration was performed as described
in numerous previous studies [11, 13, 18, 19, 22]. Never-
theless, in order to supply a better understanding of the
parameters used for detecting eEPCs from the blood and
for evaluating eEPC regeneration, the methodical ap-
proaches shall be outlined more in detail. Quantification
of peripheral circulating eEPCs was performed by flow
cytometry. Mononuclear cells (MNCs) were isolated by
density gradient centrifugation using Histopaque-1077 so-
lution (Sigma Diagnostics, St. Louis, MO) from ≈ 7.5 ml of
heparinized peripheral blood. Cells were initially incu-
bated for 1 h (on ice) using the following antibodies: rabbit
anti CD133 (ab16518 – Abcam, Cambridge, UK), mouse
anti human VEGFR2 (Vacular Endothelial Growth Factor
Receptor 2 - KDR, directly conjugated - FAB 3571 F –
R&D Systems, Minneapolis, MN, USA), followed by sec-
ondary incubation with PE-conjugated goat anti rabbit
Fab (VEGFR, 111-116-144 – Jackson Immunoresearch,
Baltimore, PA, USA) for 30 min on ice, respectively. After
incubation, cells were washed with PBS-BSA 1 % (w/v).
Data were acquired using a FACScalibur cytometer
(Becton Dickinson, Heidelberg, Germany) equipped
with a 488 nm argon laser and a 635 nm red diode
laser and analyzed using CellQuest software (Becton
Dickinson, San Jose, CA, USA). The setup of FACSca-
libur was performed according to the manufacturer’s
instructions using unstained and single-antibody
stained cells. Specificity of staining was controlled by
incubation with isotype-matched immunoglobulins.
To quantify eEPCs, the numbers of CD133/KDR double-
positive cells within the myelomonocytic cell population
were counted. eEPC regeneration on the other hand was
evaluated by a Colony-Forming Units (CFU) assay. The
assay was performed by using the EndoCult Liquid
Medium Kit® (StemCell Technologies, Vancouver, BC,
Canada) per the manufacturer’s protocol. MNCs were re-
suspended in complete EndoCult medium and seeded at
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5 × 106 cells/well on fibronectin-coated tissue culture
plates (BD Biosciences, Rockville, MD, USA). After 48 h,
wells were washed with media and nonadherent cells were
collected. Nonadherent cells were plated in their existing
media at 106 cells/well in 24 well fibronectin-coated tissue
culture plates for three days. Only colonies with at least
20 cells, containing rounded cells in the middle and elon-
gated cells at the periphery, were considered as CFU-EC
(Colony Forming Unit-Endothelial Cell) colonies. The
numbers of colonies (colonies/well) appearing after this
period were counted. At least two members of the labora-
tory staff evaluated the numbers. They were blinded for
the diagnosis and status of the investigated patients/con-
trols. The phenotype of cells within the colonies was de-
termined more in detail. For this purpose, cells were
characterized by the uptake of DiI-labeled acetylated low
density lipoprotein (Dil-acLDL) (Invitrogen, Carlsbad, CA,
USA) and binding of FITC-labeled UE lectin (Sigma Diag-
nostics, St. Louis, MO). Cells were first incubated with
10 μg/ml DiI-ac-LDL at 37 °C for 1 h and later fixed with
2 % formaldehyde for 10 min, followed by incubation with
UE(Ulex Europaeus) lectin at 37 °C for 1 h. In some ex-
periments, cells were additionally stained for FSP-1 (see
below). The number and of Dil-acLDL+/UE lectin +/ FSP-
1+cells was counted by laser scanning microscopy using
an inverted fluorescence microscope IX-71 (Olympus
Deutschland GmbH, Hamburg, Germany) equipped with
the appropriate excitation and emission filters (AHF Analy-
sentechnik, Tübingen, Germany). In order to provide some
information about concistency of the CFU-EC assay, we
compared the cumulative mean colony numbers aquired
from healthy controls evaluated in three different studies
from the past [19, 22]. One of the three studies has not
been published yet. The mean number of colonies in all
studies was 29.9 ± 2.2. It did not significantly differ from
the current mean in healthy controls (p = 0.15).
Mesenchymal transdifferentiation analysis
For mesenchymal transdifferentiation analysis mono-
nuclear cells, isolated by density gradient centrifugation
using Histopaque-1077 solution (Sigma Diagnostics, St.
Louis, MO) were seeded on fibronectin-coated dishes in
EGM-2 medium (Endothelial cell medium-2, Clonetics,
Lonza, Walkersville, MD, USA) at 5 × 106 cells/well.
After two days, non-adherent cells were removed and
adherent cells were cultured for five further days in
EGM-2. Cells were washed with PBS/BSA 1 % and pri-
mary incubation was performed with the following anti-
bodies: Mouse Anti-Human CD31 (DAKO, M0823),
Rabbit Anti-Human aSMA (alpha Smooth Muscle Actin)
(Abcam, ab32575), or Rabbit Anti-Human FSP-1 (Fibro-
blast Specific Protein-1) (DAKO, A5114). Incubation
was done for 12 h at 4 °C overnight in a humidified
chamber. After washing the cells once with PBS/BSA
1 %, secondary incubation was performed for 1 h at
room temperature using the following antibodies:
Alexa Fluor 488 donkey anti-mouse or Alexa Fluor 555
donkey anti-rabbit. After additional washing steps cells
were coated with DAPI containing Vectashield Mounting
Medium (Sigma-Aldrich, Taufkirchen, Germany). The
percentages of CD31+, and of CD31+/aSMA+, cells were
counted by laser scanning microscopy using the same
microscope as described above (inverted fluorescence
microscope IX-71 - Olympus Deutschland GmbH,
Hamburg, Germany). Results were given as percentages of
double-positive cells per nuclei.
Elisa studies
Measurements of serum Angiopoietin-1 and −2, VEGF,
TGF-beta (Transforming Growth Factor-beta), and PDGF
(Platelet Derived Growth Factor) were performed using
commercially available kits (all from R&D, Wiesbaden,
Germany) according to the manufacturer’s protocol.
Serum stimulation of cultured eEPC and eEPC migration
assay
For serum stimulation and cell migration experiments, a
commercially available human EPC cell line was employed
(Human CD133+ Endothelial Progenitor Cells, BioChain,
CA, USA). Cells were seeded after the 4th passage on
gelatine-coated 24-well plates. The migration assay was
performed as described previously (18). In detail, an artifi-
cial wound was created after the cells completely covered
the dish in a homogenous manner. A standardized stamp
was used for wound induction, allowing to create compar-
able wound areas. Shortly before wound induction, the in-
cubation procedure was initiated. Serum samples from
either healthy subjects or from SSc patients were diluted
in EGM-2 (serum:medium-ratio = 1:5 or 1:7.5) and 600 μl
were administered to the cells for 8 h in total. In some ex-
periments Bosentan was additionally applied at 2000 or at
1000 ng/ml for the same period. At the beginning and 5 h
after the end of the incubation procedure, wound areas
were quantified. For analysis of EndoMT, cells were dir-
ectly grown on glass bottom slides which allowed a more
detailed microscopic investigation. The cell treatment
protocol was the same. The staining procedure for endo-
thelial (CD31) and mesenchymal markers (aSMA) and the
subsequent analyses were performed as described earlier
(see Mesenchymal transdifferentiation analysis).
Statistical analysis
The results were expressed as mean ± SEM. The means
of two populations were compared by Student’s t test.
Three or more groups were compared by two-way
ANOVA. Differences were considered significant at
p < 0.05.
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Results
Patients
A total number of 29 patients with systemic sclerosis was
included into the study. The limited form was diagnosed
in 21 (female: 19, male: 2), the diffuse type in eight pa-
tients (female: six, male: two). The mean age of all patients
was 56 ± 2.5 years with 58 ± 2.5 years in patients with
limited and 50 ± 5.7 years in patients with generalized
SS. The mean duration of the disease was 4.5 ±
0.8 years in all patients with 4.6 ± 0.9 years in limited
and 4.2 ± 1.5 years in diffuse SSc. The respective auto-
antibody profiles are shown in Additional file 1: Table S1.
Pulmonary involvement was diagnosed in one patient with
lSSc (4.7 %) and in two patients with dSSc (25 %). Other
organ manifestations were: esophagus - lSSc 28 % (n = 6),
dSSc 37.5 % (n = 3), joints - lSSc 47.6 % (n = 10), dSSc
50 % (n = 4), kidney - lSSc 9.5 % (n = 2), dSSc 0 % (n
= 0). Fourteen patients with lSSc (66 %) and three patients
with dSSc (37.5 %) suffered from (systemic) arterial hyper-
tension. Digital ulcers were diagnosed in three patients
with lSSc (14.2 %) and in two subjects (25 %) with dSSc.
At the time of inclusion into the study immunomodula-
tory/immunosuppressive treatment was performed in five
patients (cyclophosphamide 1, prednisolone only 2, pred-
nisolone + azathioprine 1, interferone 1) with limited and
in three patients (azathioprine 1, cyclophosphamide 1,
cyclosporine A 1) with generalized disease. One patient
with dSSc (12.5 %) received Bosentan for treating pulmon-
ary hypertension. Additional file 1: Table S1 summarizes
the clinical characteristics.
eEPC numbers and regeneration
Total numbers of circulating eEPCs (CD133+/Flk-1+
cells) significantly differed between controls and SSc
patients: Controls 14.6 ± 2.9 %; SSc all 0.4 ± 0.1 %; lSSc
±0.4 0.1 %; dSSc 0.5 ± 0.3 %; the respective p-values
were: Controls vs. SSc all p < 0.0001; Controls vs. lSSc
p < 0.0001; Controls vs. dSSc p = 0.04 (Fig. 1). As op-
posed to previously published studies in certain rheumatic
diseases (RA (Rheumatoid Arthritis), GPA (Granulomato-
sis with Polyangitis) (11, 22)) eEPC colony numbers were
not different between the groups: Controls 21.8 ± 4.1; SSc
all 20 ± 3; lSSc 20 ± 3.6; dSSc 19.8 ± 5.6; the respective
p-values were: Controls vs. SSc all p = 0.7; Controls
vs. lSSc p = 0.7; Controls vs. dSSc p = 0.8 (Fig. 1).
Mesenchymal transdifferentiation of blood-derived eEPC
Since SSc is characterized by collagen deposition in vari-
ous types of tissues/organs, we aimed to investigate if
phenotypic alterations of blood-derived eEPC possibly
accompany the process of localized/generalized fibrosis.
Our particular interest focused on the de-novo expres-
sion of mesenchymal marker proteins by the cells. Thus,
mononuclear blood cells, cultured according to an
established protocol for eEPC expansion were stained
for CD31 and alpha-Smooth Muscle Antigen (aSMA).
Patients with SSc (SSc all and lSSc) showed significantly
higher percentages of CD31+ cells as compared to
healthy controls whereas dSSc patients did not: Controls
72 ± 12 %; SSc all 94 ± 1.9 %; lSSc 95 ± 1.3 %; dSSc 92 ±
4.6 %; the p-values were: Controls vs. SSc all p = 0.01;
Controls vs. lSSc p = 0.03; Controls vs. dSSc p = 0.18
(Fig. 2). In addition, percentages of CD31+ cells express-
ing aSMA were also higher in both, SSc all and lSSc:
Controls 65 ± 13 %; SSc all 90 ± 2.8 %; lSSc 92 ± 2.1 %;
dSSc 88 ± 6.7 %; the p-values were: Controls vs. SSc
all p = 0.01; Controls vs. lSSc p = 0.02; Controls vs.
dSSc p = 0.17 (Fig. 2).
These results were further confirmed by an additional
analysis, using the mesenchymal marker FSP-1 (23).
Cultured mononuclear cells were stained for UE lectin,
acLDL, and FSP-1 and percentages of triple-positive
cells were significantly elevated in all patients with SSc










































Fig. 1 Percentages of peripheral circulating eEPC and eEPC regeneration
in SSc. a shows CD133+/Flk-1+ cells (eEOCs). Percentages of
double-positive cells significantly differed between Controls and
all SSc categories (SSc all, lSSc, and dSSc) with lower values in SSc
patients, respectively. b shows eEPC colony formation. Colony Forming
Unit-Endothelial Cells (CFU-Ecs) were not different between the categories
(Data as mean ± SEM, ✻ : p< 0.05 - for exact p-values see text)
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all 74 ± 7 % and lSSc 85 ± 3 % vs. controls 38 ± 2 %,
p = 0.01 and p < 0.0005 - Fig. 2).
Angiomodulatory/profibrotic mediators
Serum concentrations of distinct vasomodulatory and
pro-mesenchymal mediators were evaluated since im-
paired eEPC regeneration has been shown to be associ-
ated with defects in the Ang-1/-2 system. In addition,
Ang-1/-2 and VEGF are known agonists of eEPCs under
certain circumstances and TGF-beta has been identified
as potent inductor of fibrogenesis in renal and other dis-
eases [23, 24]. Concentrations of Angiopoietin-1 and −2,
Platelet Derived Growth Factor (PDGF), and Vascular
Endothelial Growth Factor (VEGF) did not differ between
controls and either all patients with SSc, or with lSSc/dSSc
(Ang-1 in pg/ml: Controls 2595 ± 609; SSc all 3309 ± 484;
lSSc 2958 ± 418; dSSc 4478 ± 1530; all p-values >0.05;
Ang-2 in pg/ml: Controls 1506 ± 162; SSc all 1877 ± 374;
lSSc 1805 ± 429; dSSc 2117 ± 760; all p-values >0.05;
VEGF in pg/ml: Controls 35 ± 10.5; SSc all 58 ± 12.8; lSSc
55 ± 16; dSSc 67.5 ± 14.3; all p-values >0.05; PDGF in pg/
ml: Controls 48.8 ± 13; SSc all 77.7 ± 10.5; lSSc 67.5 ± 9.6;
dSSc 111.7 ± 28.7; all p-values >0.05).
Transforming Growth Factor-beta (TGF-b) was signifi-
cantly higher in all patients with SSc as compared to the
Controls (TGF-b in pg/ml: Controls 4549 ± 677; SSc all
6259 ± 495; lSSc 6057 ± 533; dSSc 6935 ± 1246; p-value
for Controls vs. SSc all 0.049) (Fig. 3).
Serum-induced eEPC migration and mesenchymal
transdifferentiation
Finally, serum samples from healthy subjects and SSc
patients were used for incubating cultured human
eEPCs, followed by analysis of cell migration and mesen-
chymal transdifferentiation. Five hours after wound in-
duction migration of eEPC, treated with serum from SSc
patients was significantly slower as compared to those
incubated with serum from healthy subjects (wound area
reduction in %: healthy subjects 60 ± 2.9; SSc patients
38 ± 1.7; p < 0.0001). Simultaneous Bosentan administra-
tion to the culture medium reduced migration in the
‘healthy subject’ but not in the ‘SSc’ category (wound
area reduction in %: healthy subjects 49 ± 3.5; SSc pa-
tients 35 ± 2.5; p for healthy subjects with versus without
Bosentan administration 0.03). These effects exclusively
occurred under the following conditions: serum:me-




Fig. 2 Mesenchymal transdifferentiation of blood-derived eEPCs in
SSc. Expression CD31 was significantly higher in all patients with SSc
and in lSSc, dSSc did not differ from Controls (a). b displays aSMA in
CD31+ cells with higher percentages in SSc all and in lSSc. c shows
results of additional marker staining (FSP-1), the results were comparable















Fig. 3 Pro-mesenchymal TGF-b in SSc. All Patients with SSc (SSc all)
showed higher concentrations of TGF-b as compared to healthy
controls (Data as mean ± SEM, ✻: p < 0.05 - for exact p-values see text)
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Two further experimental settings were evaluated:
serum:medium-ratio 1:7.5 with Bosentan 2000 ng/ml or
1000 ng/ml. However, although cells treated with serum
from healthy controls tended to migrate faster in all
groups, the differences as compared to SSc patients
were not statistically significant. Figure 4 summarizes
the results. Analysis of mesenchymal transdifferentia-
tion of the cells revealed comparable levels of aSMA
expression by the cells in healthy subjects and SSc pa-
tients with or without Bosentan treatment (eEPCs
stained positive for aSMA in %: healthy subjects – no
Bosentan 42 ± 8 and 33 ± 5 with Bosentan; SSc patients,
no Bosentan 29 ± 7 and 33 ± 6 with Bosentan – Fig. 4).
The differences were not statistically significant be-
tween any of the respective categories.
Discussion
The two fundamental results of the current study were
(I) the lower percentages of circulating eEPC all analyzed
categories (SSc all, lSSc, dSSc) and (II) the pro-
mesenchymal switch of cultured blood-derived eEPCs in
SSc in general and in lSSc in particular. Another inter-
esting finding was related to reduced migratory activity
of cultured eEPCs in the presence of serum from SSc
patients
The life-threatening nature of systemic sclerosis results
from two pathological phenomenona: limited or general-
ized fibrosis and vascular obstruction/occlusion [25].
The latter is critically mediated by endothelial cell prolif-
eration with subsequent intimal hyperplasia [26]. The















































Fig. 4 eEPC migration and EndoMT in vitro. Cultured human eEPCs were treated with serum samples from healthy controls, and from patients
with SSc with versus without simultaneous administration of Bosentan to the culture medium. Analysis were performed at 5 h after beginning of
the incubation. In general, migration of eEPC treated with patient serum was significantly slower (a). Bosentan reduced cellular migration in the
‘healthy subjects’ category. This effect exclusively occurred under the following experimental conditions: serum:medium-ratio 1:5, Bosentan concentration
2000 ng/ml. Expression of aSMA by the cells was comparable in all categories with no significant alteration by Bosentan (b – experimental conditions:
serum:medium-ratio 1:5, Bosentan concentration 2000 ng/ml) (bos.: Bosentan; ‘serum’ represents the serum:medium-ratio; Data as mean ±
SEM, ✻: differences between healthy subjects and SSc patients within a group significant with p < 0.05; #: differences between healthy
subjects between two groups significant with with p < 0.05)
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have been studied in recent years but the current
knowledge is still very limited. Among the factors that
have been suggested to contribute to endothelial prolifera-
tion/functional transformation were chemical substances,
vasculotropic viral pathogens, anti-endothelial cell auto-
antibodies, and others [2, 26–32]. In this context it has
to be recognized that the endothelium does not only
increasingly proliferate but also (most likely) under-
goes a process of mesenchymal transdifferentiation or
Endothelial-to-Mesenchymal Transition (EndoMT)
[25]. In other situations, EndoMT has been docu-
mented to perpetuate cardiac and renal fibrosis [33–35].
SSc-related fibrogenesis significantly results from intersti-
tial accumulation of myofibroblasts and these cells are be-
ing discussed to, at least in part originate from the
vascular endothelium [25]. The microenvironmental
humoral milieu is substantially affected in SSc. In a
more recent study Guiducci and colleagues showed SSc-
derived Mesenchymal Stem Cells (MSCs) to release nu-
merous bioactive/proangiogenic factors that potentially
stimulate angiogenesis and fibrosis (SDF-1, VEGF, TGF-
beta) [36]. Such alterations, which are partly reflected by
increases of circulating pro-mesenchymal substances
(TGF-b - see results) may promote endothelial transdiffer-
entiation into cells with mesenchymal properties. Several
studies showed a critical role for Transforming Growth
Factor-beta in mediating EndoMT [23, 35]. Early Endothe-
lial Progenitor Cells have been documented to stabilize
the microvasculature mostly by indirect mechanisms in-
cluding the release of vasomodulatory mediators in close
proximity to the endothelium [17]. Thus, eEPCs maintain
the integrity of blood vessels under both, physiological
and pathological conditions. The increased expression of
mesenchymal proteins by the cells in SSc (SSc all and
lSSc) has two possible implications. Firstly, it poten-
tially reflects the inability of the cells to stabilize the
endothelial ‘identity’ in a way that EndoMT ensues.
Secondly, it is not a hallmark of functional eEPC in-
competence but an attendant phenomenon of the
complex humoral and cellular events that occur dur-
ing the process leading to SS-associated fibrosis and
vasculopathy. Regarding EndoMT, it can only be spec-
ulated whether dSSc patients did not show signifi-
cantly higher percentages of CD31+/aSMA+ and
acLDL+/BS-1+/FSP-1+ cells as compared to the Con-
trols. In general, dSSc is associated with more severe
end organ damage including more aggravated fibrosis
and often higher risk and prevalence of digital ulcers.
It somehow surprises that in comparison to controls,
the two mentioned cell populations were not higher in
dSSc. However, in the latter group immunosuppressive
treatment was performed in 37.5 % as opposed to 23.3 %
in the lSSc group. Low-dose chemotherapy for instance
has been shown to reduce EPC mobilization into the
blood of cancer patients [37]. Thus, the lack of differences
between controls and dSSC may potentially also result
from therapy-associated effects.
Another interesting result of our study was related to
circulating eEPCs and to eEPC regeneration. CFU-ECs
have been evaluated in several own studies, with altered
colony formation in all investigations published so far
[11, 13, 18, 19, 22]. The current study did not reveal im-
paired eEPC regeneration but a significant lack of circu-
lating cells in all categories. One may argue that SSc is
characterized by increased eEPC turnover, due to gener-
alized microvascular damage and repair. In this respect,
the normal colony numbers may reflect stimulated re-
generation as well which nevertheless is not sufficient to
compensate peripheral cell degradation. Nevertheless, to
draw any definite conclusions is surely too early yet. At
this point it has to be realized that other studies related
to EPCs in SSc showed results, seemingly conflicting
with our data. Allanore and colleagues found increased
levels of CD34+/CD133+ cells in SSc as compared to
osteoarthritis patients [14]. Firstly, it still can be argued
whether CD34+/CD133+ cells truly represent circulating
eEPCs, whose proliferative potential was investigated by
us. Fadini et al. discussed the origin and phenotype of dif-
ferent EPC subtypes in a very detailed manner [17] and it
can be doubted that the cells cultured in our study exclu-
sively arise from CD34+/CD133+ cells. In addition, several
own investigations showed that eEPC regeneration and
numbers of circulating CD133+/KDR+ cells do not neces-
sarily correlate in a positive manner [11, 13, 19].
Serum from SSc patients significantly reduced eEPC mi-
gration, a phenomenon which remained unaffected by
Bosentan administration. After being incubated with
serum from healthy Controls however cell migration was
inhibited, potentially indicating that the cells were at least
capable of interacting with the substance. Thus, serum
from SSc patients may have reduced the cellular response
to Bosentan which possibly indicates some degree of func-
tional cell incompetence or Endothelial (Progenitor Cell)
Dysfunction (ED) (37). In the past, anti-endothelin therapy
has successfully been used in SSc with digital vasculopathy
[38, 39] and endothelin has also been suggested to mech-
anistically contribute to the progression of SSc-associated
fibrosis [40].
We would finally like to shortly discuss some limita-
tions of the current study. In general, monitoring mes-
enchymal properties of circulating cells such as eEPCs
allows to conclude about microvascular abnormalities
only in an approximative manner. Secondly, the de-novo
appearance of mesenchymal characteristics in eEPCs
may potentially occur as bystander phenomenon within
a systemic ‘pro-mesenchymal’ milieu. Thus, any eEPC
‘responsibility’ for aggravated skin and end-organ fibrosis
may not be assumed. Finally, eEPCs represent only one
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of two EPC subpopulations. Investigations performed
in recent years indicate that late EPCs (lEPCs) most
likely are true progenitors of the endothelium whereas
eEPCs support endothelial regeneration by indirect
mechanisms [41]. Therefore, further studies should
also address the role of the latter in SSc-associated fi-
brosis and microvasculopathy.
Conclusions
In summary, the eEPC system, which represents an essen-
tial element in the endogenous vascular repair machinery is
severely affected in SSc. The increased appearance of mes-
enchymal properties in eEPC may indicate that alterations
of the cells contribute to or at least perpetuate the accumu-
lation of connective tissue and the vascular malfunction.
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